Status:
RECRUITING
A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors
Lead Sponsor:
Janssen Research & Development, LLC
Conditions:
Advanced-stage Solid Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine safe and effective dose (recommended phase 2 doses \[RP2Ds\]) of JNJ-89862175 in Part 1 (dose escalation), and to further evaluate how safe JNJ-89862175 is at...
Eligibility Criteria
Inclusion
- Participants must have histologically or cytologically confirmed, metastatic or unresectable solid tumor of lung adenocarcinoma, renal cell carcinoma (RCC): clear cell or papillary carcinoma, endometrioid ovarian cancer and endometrioid uterine carcinoma
- Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1 at screening
- Participants on study drug and for 4 months after the last dose of study drug must not breastfeed or be pregnant, not donate gametes (that is, eggs or sperms) or freeze for future use for the purposes of assisted reproduction and wear an external condom
Exclusion
- Active central nervous system (CNS) involvement unless clinically stable
- History of clinically significant cardiovascular disease within 6 months prior to signing informed consent
- History of solid organ or hematologic stem cell transplantation
- Known allergies, hypersensitivity, or intolerance to excipients of JNJ-89862175
- Has prior or concurrent second malignancy (other than the disease under study) in which the natural history or treatment is likely to interfere with safety endpoints or efficacy of the study drug
Key Trial Info
Start Date :
October 10 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 15 2028
Estimated Enrollment :
360 Patients enrolled
Trial Details
Trial ID
NCT07223125
Start Date
October 10 2025
End Date
August 15 2028
Last Update
December 24 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
AdventHealth Orlando
Orlando, Florida, United States, 32803
2
NEXT Oncology
Irving, Texas, United States, 75039
3
Gustave Roussy
Villejuif, France, 94805